Osteoporosis in Men: A Review of an Underestimated Bone Condition
A comprehensive review highlights that male osteoporosis affects 1-2 million U.S. men, yet up to 95% of men with hip fractures are discharged without osteoporosis treatment.
Read the original article at International Journal of Molecular SciencesKairos™'s Take
Kairos™'s perspective on this story
A 2021 review published in the International Journal of Molecular Sciences laid out the scope of a problem that clinical practice has largely ignored: osteoporosis in men. An estimated 1 to 2 million American men have osteoporosis, and another 8 to 13 million have osteopenia. Yet the diagnosis and treatment rates are staggeringly low. Studies cited in the review found that up to 95% of men hospitalized for hip fractures are discharged without any osteoporosis workup or treatment. Men are also twice as likely as women to die within one year of a hip fracture, making the underdiagnosis not just a gap in care but a direct contributor to preventable mortality.
The review also highlighted that secondary causes of osteoporosis are more prevalent in men — found in roughly two-thirds of male cases compared to about one-fifth in women. Hypogonadism, glucocorticoid use, alcohol excess, and androgen deprivation therapy for prostate cancer are among the most common drivers. This means that male osteoporosis often has an identifiable, treatable underlying cause that goes undetected because nobody looks.
Why This Matters for Midlife Health
Osteoporosis is not a women's disease. It is a bone disease. The hormonal mechanisms differ — testosterone decline is more gradual than the estrogen cliff of menopause — but the endpoint is the same: weakened bones, fragility fractures, and life-altering consequences. Men in midlife, particularly those with risk factors like long-term corticosteroid use, low testosterone, or a family history of fractures, deserve the same proactive assessment that women receive. The current screening guidelines do not mandate it, which means men have to advocate for themselves.
The Tracking Connection
Kairos™ is built for both women and men navigating midlife hormonal changes. For men, that means tracking testosterone levels, symptoms of hormonal decline, medication history, and bone health metrics. When the system does not screen you by default, your own health record becomes the trigger. Bringing documented risk factors and symptom patterns to a provider visit is how men close the gap between what guidelines recommend and what actually happens in clinical practice.
Ready to start tracking?
Kairos™ tracks, scores, and interprets the symptoms of midlife hormonal change — for both women and men.
Get StartedMore from the newsroom
SWAN Study: Bone Loss Accelerates Sharply During the Menopause Transition
The landmark SWAN longitudinal study showed that bone mineral density remains stable in early perimenopause but declines sharply in late perimenopause — about 2% per year — continuing into early postmenopause.
The FREEDOM Trial: Denosumab Reduces Vertebral Fractures by 68% in Postmenopausal Women
The landmark FREEDOM trial published in NEJM showed that denosumab, a monoclonal antibody, significantly reduced vertebral, hip, and nonvertebral fractures in women with osteoporosis over 3 years.
The Treatment Gap in Osteoporosis: Fewer Than 20% of High-Risk Patients Receive Care
A comprehensive review documents the growing osteoporosis treatment gap — with diagnosis rates below 20% and post-fracture treatment rates declining despite effective therapies being available.